Avandia generic rosiglitazone, was founded in 1999 by the FDA (Food and Drug Administration) for the treatment of type 2 diabetes. It is estimated that around six million people worldwide take the drug treatment of type 2 diabetes. An article published in the New England Journal of Medicine late in May 2007 found that among Avandia increases the risk of heart attacks in diabetes patients. In response to the article, the FDA issued a warning advising people taking public safetyAvandia to consult their doctor about the cardiovascular risks associated with taking the drug linked.
After analyzing dozens of studies, it was concluded that Avandia increases the risk of heart attack by 43% and heart-related deaths by 64%.
GlaxoSmithKline, the maker of Avandia, issued a press release to defend themselves and the drug. Glaxo is a challenge, the data in the New England Journal of Medicine presented study, stating that it is too early to be concluded thatAvandia increases the risk of cardiovascular problems in type-2 diabetes patients.
But in 2000, said Dr. John B. Buse, director of endocrinology at the University of North Carolina at Chapel Hill, wrote to the FDA warning that Avandia showed "a worrying development of cardiovascular deaths and severe adverse events "in patients taking the drug. In July 2001, the FDA Glaxo sent a letter in which the company's sales representatives had the drug affects the safety minimized, the FDAGlaxo asked to participate send a letter to doctors, Avandia, she warned of the serious risks associated with taking the drug prescription to be sent.
Obviously, both the FDA and the manufacturer of Avandia have known about the potential risks associated with cardiovascular drug for more than six years of association, but not sufficiently warn prescribers and consumers about the deadly effects of the drug. In 2000, Dr. Buse's letter to the FDA criticized Glaxo and the company gave the "pervasive and systemic" efforts toMinimizing overstate the drug benefits and drug benefits. The FDA sent a warning letter to doctors, but not taken decisive action has been, and continue to be prescribed the drug in the world.
Lawyers for Glaxo said they are always calls from Avandia users and predict future claims could reach into the tens of billions of dollars. Plaintiff lawyers certainly jack on the years of warnings about cardiovascular risks that were all but ignored by the developersAvandia.
